Liquidia Corporation (LQDA) Stock: Price, Forecast & Analyst Target
Liquidia Corporation (LQDA) — MoonshotScore 36/100 (Weak band), calculated Nov 18, 2026. Price $56.63 (+0.41%), as of the Nov 19, 2026 trading session; market cap $5.10B. Expected results Mar 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Liquidia Corporation · LQDA · NASDAQ · Healthcare · Medical - Pharmaceuticals
Research dated 2026-09-13: Liquidia is a biopharmaceutical company that sells pulmonary arterial hypertension therapies. The central question: can the company sustain the inflection from losses to profitability and continue expanding without exhausting its cash cushion? After years of setbacks, the company just posted profits in consecutive quarters, driven by uptake of YUTREPIA, an inhaled formulation of treprostinil. The rate of growth and the management's commitment to spending more on research while maintaining margin expansion will determine whether the current trajectory holds.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Liquidia (LQDA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 0 of the last 3 reports
- Altman Z 3.31 · Piotroski F 4
Helping: durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $56.63 | |
| Change on the day | +0.41% | |
| 52-week range | $22.31–$93.61 | |
| Market capitalisation | $5.10B | — |
| Price / earnings (trailing) | 30.51 | |
| Shares traded on the day | 1.32M | |
| Beta (volatility vs the S&P 500) | 0.54 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Liquidia (LQDA): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Liquidia (LQDA), and what does it report?
Short answer · as of
Liquidia manufactures inhaled treprostinil (YUTREPIA) and distributes a generic injectable version of the same molecule.
Research dated 2026-09-13.
The inhaled form is the innovation: it changes the route of administration from injection to inhalation, which alters dosing burden and patient tolerability in pulmonary arterial hypertension, a rare lung disease characterized by elevated pressure in pulmonary arteries. The company also earns revenue from services, but products dominate the mix.
Reported numbers measure net product and service revenue against operating costs and R&D spending. The critical reading is that this is not a pure-play development company anymore. Results show a commercial-stage enterprise whose inhaled treprostinil formulation is generating significant adoption, and management is deliberately scaling research to develop additional inhaled treprostinil products rather than expanding into unrelated molecules.
What do the latest results show for Liquidia (LQDA)?
Research dated 2026-09-13.
Revenue accelerated sharply over recent periods, with each period showing growth over the prior year. The magnitude of that acceleration widened. Profitability swung from significant losses through prior calendar periods to a series of positive net results in the current fiscal year. The swing reflects both the revenue uptick and the operating leverage embedded in the cost structure: gross margins are elevated, and SG&A has not grown in proportion to revenue gains. Management commentary signals intent to increase R&D spending in the second half of the current year relative to the first half, and again in the following calendar year. The stated expectation is that revenue will continue to expand while profitability grows in absolute terms—a claim that hinges on the continued adoption rate of the inhaled formulation and the company's ability to manage the new research investments without creating a cost structure that revenue cannot support.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $225.30M Nov 10, 2026
- Latest report · revenue estimate
- $214.18M Nov 10, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 10, 2026
- Latest report · EPS vs estimate
- Below estimate Nov 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 10, 2026 | $225.30M | $214.18M | −$2.6400 | $0.9600 |
| Aug 12, 2026 | $171.68M | $168.48M | $0.7400 | $0.7000 |
| May 11, 2026 | $132.87M | $119.44M | $0.5200 | $0.3400 |
| Mar 5, 2026 | $92.02M | $88.59M | $0.1500 | $0.0800 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $54M | -$4M | -$0.04 (diluted) |
| Q4 FY2025 | $92M | $15M | $0.15 (diluted) |
| Q1 FY2026 | $133M | $53M | $0.52 (diluted) |
| Q2 FY2026 | $172M | $75M | $0.74 (diluted) |
What are the financial strengths and risks for Liquidia (LQDA)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The balance sheet shows abundant cash relative to debt, and the gap widened in recent quarters. The company holds no long-term investments and minimal capital spending. Cash generation from operations turned sharply positive in the most recent quarter after declining in intermediate quarters, which suggests the shift to profitability is material and not a one-off timing effect.
Management commentary and the quality screening metrics indicate the company is not in financial distress. The runway calculation derived from current cash and annualized cash use spans multiple years, providing buffer for increased R&D and any disruption in revenue growth. The specific risk is not solvency but rather whether the inherent profit margin of treprostinil products—now that they have reached meaningful volume—can support both higher R&D and investor expectations for sustained growth.
What should you watch next at Liquidia (LQDA)?
Short answer · as of
The next earnings report is expected on Mar 4, 2027.
Research dated 2026-09-13.
Analyst revenue estimates for the next several years assume accelerating topline results, driven by continued adoption of the inhaled formulation. The estimates imply margin expansion, meaning revenue growth is expected to exceed cost growth. The next reported earnings will provide the first test of whether the company's guidance on R&D investment is consistent with those estimates.
Insider transactions over the recent period show selling concentrated among officers, with no recorded purchases. The pattern suggests either tax-motivated withholding on vesting compensation or a signal of confidence in the current valuation; Form filings do not distinguish between them. Monitor the earnings call and any announcements about clinical development in the near term, as those will signal whether management is executing on the R&D scaling it has announced.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Liquidia compare with its peers?
Short answer
Liquidia's score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Pulmonary arterial hypertension therapies fall into several categories: intravenous, subcutaneous, inhaled, and oral formulations of various compounds. Liquidia's inhaled treprostinil occupies a distinct position because inhalation is a non-invasive delivery route for a molecule that has existing data in other forms. The commercial advantage is reduced treatment burden compared to injected routes.
Liquidia differs from other treprostinil producers and PAH therapy makers in that it owns both the advanced formulation (inhaled) and the commodity form (generic injectable). That vertical integration—owning both premium and generic lines—provides revenue diversification and supply chain control. The trade-off is that it exposes the company to margin compression if generic pricing becomes competitive pressure, though the injectable is not the growth driver in current results.
| Company | Price | Market value | Score |
|---|---|---|---|
| $403.60 Nov 18, 2026 | $46.1B | 96 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $589M | 51 5-pillar Nov 18, 2026 | |
| $27.74 Nov 19, 2026 | $4.83B | 50 5-pillar Nov 18, 2026 | |
| $24.30 Nov 19, 2026 | $1.50B | 50 5-pillar Nov 18, 2026 | |
| $2.51 Nov 19, 2026 | $22.1M | 40 5-pillar Nov 18, 2026 | |
| Liquidia (LQDA) — this page | $56.63 | $5.10B | 36 |
| $2.29 Nov 19, 2026 | $204M | 36 5-pillar Nov 18, 2026 | |
| $5.80 Nov 19, 2026 | $123M | 32 5-pillar Nov 18, 2026 | |
| $1.83 Nov 19, 2026 | $7.41M | 32 5-pillar Nov 18, 2026 | |
| $0.37 Nov 19, 2026 | $31.7M | 30 5-pillar Nov 18, 2026 | |
| $0.90 Nov 18, 2026 | $20.0M | 29 5-pillar Nov 18, 2026 | |
| $18.75 Nov 19, 2026 | $133M | 22 5-pillar Nov 18, 2026 | |
| $1.61 Nov 19, 2026 | $57.9M | 21 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $54.00 – $130.00
- Consensus target
- $78.18
- Median target
- $65.00
Consensus record · Captured .
Measured against a quoted price of $56.63 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 26, 2026
- Transactions
- 181
- Identified insiders
- 17
- Purchases
- 0
- Sales
- 89
- Other transactions
- 92
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LQDA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LQDA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Liquidia (LQDA)?
LQDA Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does YUTREPIA do that other treprostinil products do not?
YUTREPIA is an inhaled dry-powder formulation of treprostinil, which means it reaches the lungs directly without requiring intravenous or subcutaneous injection. This avoids the need for central lines or needle insertion and offers dosing flexibility for pulmonary arterial hypertension patients. The molecule itself—treprostinil—is an established prostacyclin analogue; the innovation is in the delivery mechanism.
Can the company fund the R&D increase it has announced without depleting cash?
Current cash and the trajectory of operating cash flow—positive in the most recent quarter—suggest the company has sufficient liquidity to fund that investment while continuing to grow absolute profitability. The risk is not bankruptcy but rather whether the revenue growth assumption underlying analyst estimates holds.
Why are insiders selling if the business is performing this well?
Insider filings show net selling concentrated over a narrow window, with transactions classed as equity compensation withholding (M-Exempt category) dominant in the total. Withholding on vesting shares is tax-driven and does not necessarily signal a view on the company's prospects. However, the absence of any insider purchases over the recent period is notable and warrants attention to the earnings call commentary and any clinical or competitive announcements that might explain executive caution.
What is the breakeven point for cash generation, and when might the company reach it permanently?
The company currently burns cash through operating and capital spending at an annualized rate that is well below the operating profit it posted in the most recent quarter. This suggests operating profitability is now structural, not cyclical. The critical threshold is whether gross margin on inhaled treprostinil remains stable as volume increases, and whether SG&A growth remains proportional to revenue. If both hold, the company could approach cash-positive operations within quarters. Analyst guidance and the next earnings call will clarify the timing.
What is the LQDA stock price today?
The last price recorded for Liquidia Corporation (LQDA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LQDA price target?
The analyst consensus price target for Liquidia Corporation (LQDA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com